Physician profile
Thomas J Clinch
NPI 1568465987
$901.91
in general payments reported to CMS, 2019-2025
11 companies · $166 in 2025
The $166 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $207 · 2020: $60.48 · 2021: $18.67 · 2022: $128 · 2023: $64.41 · 2024: $257 · 2025: $166.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $488.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $487.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $278.72 | 2019-2025 | Lensx, Clareon, Wavelight Refractive Suite |
| Johnson & Johnson Surgical Vision, INC. | $189.64 | 2019-2024 | Tecnis Iol |
| Bausch & Lomb Americas INC. | $102.39 | 2023-2024 | Ic-8 Apthera Iol, Vyzulta, Xiidra |
| Allergan, INC. | $69.54 | 2019-2022 | |
| Rayner Intraocular Lenses Limited | $66.27 | 2022-2024 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Glaukos Corporation | $58.94 | 2022-2025 | Idosetr, Idose |
| Abbvie INC. | $49.02 | 2022-2024 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $40.43 | 2019-2020 | |
| Ocular Therapeutix, INC. | $19.47 | 2022 | |
| Glaxosmithkline, LLC. | $15.15 | 2024 | Bexsero |
| Omeros Corporation | $12.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Clinch listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.